CETP inhibition Reduces Cardiovascular Events by Lowering of Cumulative LDL Exposure: Reconciling Evidence from Human Genetics and Clinical Trials

Fredrik Landfors[1,2,*], John J.P. Kastelein[3,4], Elin Chorell[1]

[1] Department of Public Health and Clinical Medicine, Section of Medicine, Umea University, S-901 87 Umea, Sweden.

[2] Lipigon Pharmaceuticals AB, S-907 36 Umea, Sweden.

[3] Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, the Netherlands

[4] NewAmsterdam Pharma, Naarden, the Netherlands

[*] To whom correspondence should be addressed.

Contact information for the corresponding author: Fredrik Landfors, Department of Public Health and Clinical Medicine, Umea University, S-901 87 Umea, Sweden; Email: Fredrik.Landfors@umu.se; Phone: +46 (0) 70-454 92 08.

Abstract

Background: Genetic studies consistently demonstrate that individuals born
with reduced Cholesteryl Ester Transfer Protein (CETP) activity experience lower rates of
atherosclerotic vascular disease throughout their lives. In contrast, short-term
randomized controlled trials of CETP inhibitors have yielded mixed results, with only one
of four trials reporting a reduction in clinical events. Several theories have been proposed
to explain this discrepancy, but none fully account for the central mechanism of
atherosclerosis: the cumulative lifetime exposure to circulating low-density lipoprotein
(LDL) particles in the arterial walls.

Objectives: We aimed to reconcile these conflicting findings by examining
the relationship between cumulative LDL exposure and atherosclerosis risk across both
genetic studies and clinical trials.

Methods: We analyzed 679 carriers of *CETP* protein-truncating variants
(resulting in reduced or non-functional CETP protein) and 505,837 non-carriers in a
population with 95,568 atherosclerosis events. Additionally, we assessed treatment
effects relative to cumulative LDL reductions in 34 cardiovascular prevention trials
involving 328,036 participants and 53,161 events.

Results: Heterozygous *CETP* protein-truncating variant carrier status
reduced atherosclerotic disease risk (odds ratio, 0.70; 95% confidence interval, 0.57–
0.85; P=5×10^{-4}). In clinical trials, we observed a significant interaction between the
magnitude and duration of LDL lowering on treatment effects (hazard ratio, 0.69 per 10–
mmol/L×years; 95% confidence interval, 0.52–0.90; P=0.007), supporting that reducing
cumulative LDL exposure is key to lowering cardiovascular risk. When comparing
genetics with trial outcomes, accounting for differences in timing, duration, and follow-
up, we observed consistent effects on atherosclerosis-related events per LDL years
across genetic and pharmacological CETP inhibition, as well as with statins, ezetimibe,
PCSK9 inhibitors, and familial hypercholesterolemia-associated variants (hazard ratio,
0.74 and 0.69 per 10–mmol/L×years, respectively). This suggests that CETP inhibition
reduces cardiovascular risk primarily through LDL. Notably, several trials failed to achieve
sufficient cumulative LDL reduction to impact clinical events, and this was not unique to
CETP inhibitors.

Conclusion: Our findings indicate that future CETP inhibitor trials achieving

substantial and sustained LDL reduction will demonstrate efficacy in preventing

cardiovascular events. These results highlight the importance of long-term LDL lowering

and support further investigation of CETP inhibition as a strategy for cardiovascular

prevention.

Introduction

Cholesteryl ester transfer protein (CETP) is a lipid exchange protein found in the circulation of humans and certain higher mammals. It facilitates the transfer of cholesteryl esters from high-density lipoprotein (HDL) to low-density (LDL) or very-low-density lipoprotein (VLDL) in exchange for triglycerides[1,2] Reduced CETP activity may benefit human health by shifting plasma cholesterol from atherogenic LDL and VLDL to HDL, decreasing the number of cholesterol-containing particles that can accumulate in arterial walls, potentially slowing down atherosclerosis development.[3-5] Several studies also suggest CETP inhibition improves HDL functionality and promotes cholesterol efflux from plaque macrophages, further mitigating atherogenesis.[3,6,7] However, the precise impact of CETP inhibition on atherosclerosis remains under investigation.

CETP's contribution to atherogenesis led to the development of CETP inhibitors for atherosclerotic cardiovascular disease (ASCVD). Clinical trials of these inhibitors, however, yielded mixed results. Torcetrapib, the first inhibitor, increased cardiovascular events and mortality through off-target effects such as raised blood pressure and aldosterone levels. [8,9] Subsequent inhibitors, dalcetrapib and evacetrapib, were safe but failed to reduce cardiovascular events in outcomes trials, possibly due to insufficient LDL lowering and the short duration of the trials.[10-12] Anacetrapib showed promise by reducing ASCVD events in a phase 3 trial, but its development was halted after it was found to accumulate in adipose tissue, raising long-term safety concerns.[13,14] Obicetrapib, a less lipophilic yet potent CETP inhibitor, is currently being evaluated in phase 3 trials.[10,15] The single success among four major trials has cast doubt on CETP inhibition's therapeutic value in atherosclerosis prevention.

Early atherosclerotic lesions begin forming in childhood, and cumulative exposure to LDL drives the progression of ASCVD through plaque formation.[16,17] Therefore, evaluating the long-term effects of CETP inhibition requires considering the duration and timing of LDL cholesterol (LDL-C) lowering. Human genetics offers a way to assess the potential of such sustained CETP inhibition in preventing ASCVD. Genetic variants that naturally reduce CETP activity from conception provide a "natural experiment" to predict the long-term effects of CETP inhibition. By analyzing health outcomes in individuals carrying protein-truncating variants (PTVs) in the *CETP* gene,

which lead to reduced or non-functional proteins, we can infer the impact of lifelong CETP inhibition on ASCVD risk.[18-21] This approach minimizes confounding and reverse causation, and has proven effective in predicting drug target outcomes.[22,23]

Given the potential of CETP inhibition and the conflicting results from clinical trials, this study aimed to determine whether CETP inhibition reduces ASCVD risk by lowering LDL particles. To ensure reliable long-term estimates, we analyzed the effects of genetic CETP inhibition across diverse populations. Additionally, we tested the cumulative LDL exposure hypothesis using clinical trial data. To reconcile the conflicting findings on CETP inhibition, we introduce the concept of 'LDL-C Plaque Years,' which models the cumulative impact of LDL-C reduction over time. This enabled a direct comparison between lifelong genetic reductions and shorter-term pharmacological effects from clinical trials. By accounting for differences in timing, duration, and magnitude between genetic and clinical studies, we found that CETP inhibition lowers ASCVD risk, but only when LDL-C is significantly reduced for a sustained period.

Methods

The analyses in this paper were conducted in two sequential steps. First, we measured the impact of *CETP* PTVs on ASCVD risk in the UK Biobank and performed a meta-analysis across diverse ancestries. Second, we assessed the plausibility of these genetic results by comparing the effects of genetic and pharmacological CETP inhibition on ASCVD risk relative to their cumulative LDL-C lowering, and against guideline-recommended lipid-lowering therapies and *LDLR* PTVs (encoding the LDL receptor).

Step 1

Genetic association study of *CETP* protein-truncating variants and atherosclerotic disease

Study design and data sources

The impact of lifetime CETP inhibition on ASCVD risk was measured in *CETP* PTV carriers and non-carriers in the United Kingdom Biobank (UKB). The UKB is a population-based study that has gathered a vast array of research data, including health outcomes data, genetics, and blood chemistry from 500,000 participants across the United Kingdom.[24] The study enrolled individuals aged 40-69 between 2006 and 2010, during which blood samples were collected. Ongoing follow-up of these participants ensures that their health information is continuously updated through medical records, death certificates, and registries. The data (UKB v18.1) were released to us on January 14, 2024.

The primary outcome was ASCVD events (**TABLE 1** details the primary and secondary endpoints). Diagnoses and event dates were retrieved from the first occurrences data set (UKB data fields 131271–131423). ASCVD events were defined as the first occurring hospital-record, death certificate, or primary care diagnosis of coronary heart disease (ICD-10: I20-I25), ischemic stroke (I63), or peripheral atherosclerosis (I70). We did not consider self-reported diagnoses as being positive for an endpoint. Myocardial infarction was defined as being positive for ICD-10 codes I21–I23. Cardiovascular death was defined as any atherosclerotic event (defined above) or sudden cardiac death (I46.1) being recorded as the primary cause of the death in a death

certificate (UKB data field 40001). Major adverse cardiovascular events were defined as the first-occurring stroke, myocardial infarction, or cardiovascular death.

Exposure to a defective *CETP* allele was assumed to begin at conception, and participants were followed from their birth (UKB data fields 34, 54) until the occurrence of the first event, loss to follow-up (UKB data field 191), death (UKB data field 40000), or the end of the study period (January 1, 2023), whichever occurred first. Diabetes presence, statin medication, and smoking status were defined according to their self-reported status at enrollment between the years 2006-2010 (UKB data fields 2443, 20003, 20116). LDL-C was measured both directly (UKB data field 30780), and calculated using the Friedewald formula from total cholesterol, HDL, and triglycerides (UKB data fields 30690, 30760, 30870). Non-HDL cholesterol was calculated by subtracting HDL from total cholesterol, and remnant cholesterol was calculated by subtracting directly measured LDL-C cholesterol from non-HDL cholesterol. Apolipoprotein A1, B, and Lipoprotein(a) levels were measured using immunoturbidimetry (UKB data fields 30630, 30640, 30790). Diastolic and systolic blood pressure was measured at recruitment using automated monitors (UKB data fields 4079, 4080). The proportion of missing observations for each measure is presented in TABLE 1. Missing observations were not imputed.

Pre-processing and quality control of genetic data

To measure *CETP* PTV carrier status, we used the UK Biobank exome sequencing data (UKB data field 23157).[25] Population variant call file meta data were annotated using gnomAD v.4.1.0, and Ensembl Variant Effect Predictor v. 111 (VEP).[21,26] Variants qualified as PTVs if their impact on the MANE transcript (Matched Annotation from NCBI [National Center for Biotechnology Information] and EBI [European Bioinformatics Institute]) were annotated with VEP consequences "frameshift variant", "splice acceptor variant", "splice donor variant", "start lost", "stop gained", or "stop lost", and their allele frequency was <0.001. To prevent batch effect bias, we excluded variants with a genotype depth of coverage (DP) ≤10 or were missing in more than 90% of the population. For single nucleotide variants, we further filtered out those with a DP <10, genotype quality (GQ) <20, and a binomial test of the alternate alleles deviation from the

heterozygous expectation of 0.5 with a P-value $<1×10^{-3}$. For insertions and deletions, we removed variants with DP <10 and GQ <20. Details on the 60 different *CETP* PTVs found in the UK Biobank trans-ancestry exome sequencing sample are provided in **SUPPLEMENTAL TABLE 1**. In a sensitivity analysis, we assessed the impact of PTV loss-of-function classification using LOFTEE (Loss-Of-Function Transcript Effect Estimator).[27] We found no differences in the association between *CETP* PTV carrier status and HDL levels across high-confidence, low-confidence, or not classified PTVs, indicating that LOFTEE classifications were not relevant to *CETP* PTVs (**SUPPLEMENTAL FIGURE 1**).

Genetic association studies

The inferential validity of genetic association studies relies on the assumption that the genetic variants under investigation are distributed in a random-like pattern within the study population. This randomness typically occurs because transmission of alleles from parents to offspring, or the emergence of de novo variants, is a random-like natural process that mimics randomization in a clinical trial. Potential confounders, such as population stratification, assortative mating, or relatedness, could however impact the *CETP* PTV–ASCVD association by misbalancing the distribution of non-lipid risk factors between variant carriers and non-carriers.[28-30] This would be analogous to failure of randomization in a clinical trial. To examine if such sources of bias were present, we tested whether the distribution of non-lipid ASCVD risk factors were similar in *CETP* PTV carriers and non-carriers. *P* values and 95% confidence intervals were computed using t-tests for continuous variables and Fisher's exact test for categorical variables (see **TABLE 1**).

In the analysis of the primary endpoint, the association between *CETP* PTV carrier status and ASCVD was measured using Cox regression, adjusting for age, sex, and the six first genetic principal components (UKB data field 22009). We restricted the sample to European ancestry individuals to limit bias from population stratification. To control for excessive relatedness, only one individual from each group of individuals more closely related than third-degree relatives was selected for further analyses, based on a KING coefficient cut-off of 0.0884.[31] To reduce genotyping error, we excluded samples that were outliers for heterozygosity (principal components-adjusted heterozygosity

>0.1903) or had a missing rate >5%. We also excluded participants with sex chromosome

aneuploidies (UKB data field 22019).

A trans-ancestry meta-analysis was conducted to determine if the

inferences were valid across ancestries. We included a previous study of Nomura et al.,

to increase statistical power (80,001 individuals and 44% East Asian, 44% European, 12%

South Asian ancestry).[32] Compared to the ASCVD composite endpoint used in the UK

Biobank analyses, the outcome in the Nomura et al. paper was restricted to coronary

heart disease alone. However, both endpoints reflect the same underlying

pathophysiological phenotype, atherosclerosis, which justifies their inclusion in the

meta-analysis. The odds ratio of ASCVD between *CETP* PTV carriers versus non-carriers

was measured in 6908; 409,638; and 6969 UK Biobank participants of African, European,

and South Asian ancestry, respectively. To harmonize the unit of effect measurements

between the studies, we applied logistic regression with Firth's correction in the UK

Biobank subset, while otherwise reusing the analysis strategy described in the previous

section.[33] Meta-analysis was conducted using a fixed-effects inverse variance weighted

estimator. Study heterogeneity was estimated using Cochran's Q test and calculating the

I^2 statistic.

Step 2

Cumulative LDL cholesterol exposure and atherosclerotic cardiovascular disease risk in genetic studies and clinical trials

Selection of clinical trials and genetic exposures

A list of clinical trials was retrieved from previous systematic reviews of

guidelines-recommended lipid-lowering therapies for ASCVD prevention (see

SUPPLEMENTAL TABLE 2 for details).[34-36] We then added trials involving dialysis and heart

failure patients, one post-acute coronary syndrome trial, and the pitavastatin trials.[37-42]

The guideline-recommended therapies were statins, ezetimibe, and PCSK9 inhibitors. To

obtain precise and unbiased effect estimates, we applied specific selection criteria. First,

each trial was required to be designed to measure cardiovascular outcomes as the

primary outcome and have recorded more than 100 events. Second, trials that were

stopped early due to efficacy were excluded if the information fraction was less than 0.90,

as truncated trials tend to overestimate treatment effects, especially when the event rate is low.[43] This overestimation is sometimes referred to as the "winner's curse". The information fraction was calculated as the ratio of the pre-specified planned events to the actual observed events before termination. Third, to ensure comparability between studies, the effect had to be measured using the hazard ratio (HR) or incidence rate ratio (IRR). The inclusion of studies using IRR for measuring the primary outcome was justified since, in most cases, the IRR closely resembles the HR.[44] We performed sensitivity analyses to assess the impact of the second selection criteria (see **SUPPLEMENTAL FIGURES 2-5**). Additionally, we examined whether excluding non-double-blind trials affected the results (**SUPPLEMENTAL FIGURES 6-7**).

From each study, we extracted the reported composite outcome most closely resembling the ASCVD composite endpoint described in **STEP 1**. LDL-C reduction from treatment was obtained from the text, or if unavailable, directly from figures using a web-based tool (see **DATA AVAILABILITY**). Other key variables, such as baseline age and baseline LDL-C cholesterol, were extracted from tables, text, or supplemental materials. Regarding CETP inhibitors, we excluded torcetrapib from the meta-analysis due to its off-target toxicity.

As a genetic positive control, we assessed the effect of lifetime *LDLR* PTV carrier status (encoding the LDL receptor) on ASCVD risk in the UK Biobank. Carrying an *LDLR* PTV typically meets the genetic diagnostic criteria for heterozygous familial hypercholesterolemia, a condition characterized by increased lifetime LDL-C exposure that profoundly impacts ASCVD risk.[45] Given the focus on the impact of cumulative LDL-C differences on ASCVD, the *LDLR* PTV carriers served as a relevant genetic comparator to *CETP* PTV carriers. The association between *LDLR* PTV carrier status and ASCVD risk was measured using the same methods as described in the *CETP* PTV analyses in **STEP 1**. Additional details on the UK Biobank *LDLR* PTVs are provided in **SUPPLEMENTAL TABLE 3**. The conditional effect of *CETP* and *LDLR* PTVs on LDL-C were measured using linear regression adjusting for age, sex, and the six first genetic principal components.

LDL cholesterol exposure trajectories and calculation of cumulative LDL cholesterol

difference

Low-density lipoprotein levels are low at birth, rise with age, and stabilize in late middle age.[17,46,47] Consequently, lifetime ASCVD risk attributable to LDL-C is a time-varying exposure that needs accounting for to accurately estimate its impact.[48-50] For each intervention or genetic exposure, we quantified the reduction in cumulative LDL-C exposure, expressed as "LDL-C Plaque Years Difference", by integrating over population mean LDL-C life course trajectories (see **FIGURE 1**). First, we adjusted the standard population LDL-C trajectory to match the baseline LDL-C levels of each specific study population. This adjustment was done by scaling the mean LDL-C trajectory using the ratio of the study's baseline LDL-C level to a general population reference mean LDL-C value (3.55594 mmol/L), accounting for differences in baseline LDL-C levels between population-based studies and clinical trials involving secondary or high-risk prevention populations. The LDL-C trajectories were extracted from references,[17,46,47] and the exact population trajectories that were used are provided in **SUPPLEMENTAL TABLE 4**.

Then, we calculated the area under the LDL-C versus age curve (AUC) from the start of follow-up to the end (defined as the start age plus the median time of follow-up) to represent cumulative LDL-C exposure without intervention. To model the effect of the intervention (or genetic exposure), we adjusted the LDL-C trajectory according to the intervention's reported effect size. Our approach assumed a time-independent relative lowering of LDL-C levels across the exposure-time trajectory. To reflect this constant relative reduction of LDL-C over time, we applied a scaling factor $k = 1 + \frac{LDL-C\ Effect}{LDL-C\ Baseline\ Mean}$ across the intervention or genetic exposure trajectory. We then recalculated the AUC for the adjusted LDL-C trajectory, representing cumulative LDL-C exposure with the intervention (or genetic exposure). The difference between the two AUCs (without and with intervention) therefore reflected the total reduction in cumulative LDL-C exposure due to the intervention (or genetic exposure). These differences were computed for each study and recorded as the "LDL-C Plaque Years Difference". The measure allowed us to compare how much cumulative LDL-C exposure was lowered in each clinical trial or genetic association study. Reproducible code for these calculations is provided in the **SUPPLEMENTAL NOTE**.

Meta-analysis of genetic and pharmacological cumulative LDL cholesterol lowering and atherosclerotic disease risk

To compare CETP inhibition with the guidelines-recommended lipid-lowering therapies and *LDLR* PTVs, we conducted separate analyses for CETP and the other approaches to measure the association between cumulative LDL-C differences and ASCVD risk. We used a fixed-effects inverse variance-weighted estimator to measure the combined effect size across studies. Study heterogeneity was assessed using Cochran's Q test and the I^2 statistic. Leave-one-out sensitivity analyses of effect size and heterogeneity are presented in **SUPPLEMENTAL FIGURE 8**.

We performed additional sensitivity analyses because, if atherosclerosis follows a cumulative exposure model, both the magnitude and duration of LDL exposure (LDL-C × follow-up length) should approximately predict the observed risk reductions. We used multiple meta-regression to assess the impact of LDL-C lowering and mean or median follow-up duration on the ASCVD hazard reduction observed in clinical trials. The data were fitted with a linear random-effects mixed model, and restricted maximum likelihood estimated heterogeneity. *P* values were validated using permutation tests.[51] We performed sensitivity analyses by adjusting the interaction term (LDL-C × median time of follow-up) for baseline LDL-C, annual and cumulative event risk, age at enrollment, and year of publication, and used multilevel inference to rank them as predictors (**SUPPLEMENTAL FIGURE 10**).

Ethical review and reporting of statistical tests

This research has been conducted using the UK Biobank Resource under Application Number 148828. The LDL-C trajectory and meta-analyses used publicly available summary data that did not require separate ethical review. The research adhered to the ethical standards set forth in the Declaration of Helsinki. The primary research question in this study was to measure the impact of long-term CETP inhibition on ASCVD risk. The other statistical tests in **STEP 1** were considered secondary endpoints. **STEP 1** and **STEP 2** analyses were separate, and did not require correcting for a family-wise error rate. Consequently, *P* values and 95% confidence intervals reported in this paper are presented without correction for multiple comparisons.

Results

Step 1

Protein-truncating variants that inhibit CETP throughout life reduce the risk of atherosclerotic disease

Descriptive characteristics on the 409,638 European-ancestry individuals meeting inclusion criteria are presented in TABLE 1. The mean age at recruitment into the UK Biobank between 2006–2010 was 56.8 years and 53.9% were female. Genetic exposures begin at conception, and the median time of birth to end of follow-up was 70.2 years. Between 1958 and 2023 (median year 2013, interquartile range 2006–2018); 61,091 first occurrences of ASCVD were recorded. Details on the composite endpoints are provided in the METHODS section and FIGURE 2. UK Biobank *CETP* PTV variant types and allele frequencies are listed in SUPPLEMENTAL TABLE 1.

There were 385 European-ancestry *CETP* PTV carriers available for analysis in the UKB. As anticipated, they presented with elevated HDL cholesterol (+0.42 mmol/L, $P=9\times10^{-37}$), and lowered LDL cholesterol (-0.18 mmol/L, $P=3\times10^{-5}$). Apolipoprotein A1 and Apolipoprotein B differed according to a similar pattern (TABLE 1). Lipoprotein(a) levels were lower in *CETP* PTV carriers (-6.5 nmol/L, $P=0.021$). Statin treatment was less common in *CETP* PTV carriers (16.3% vs. 12.5%, $P=0.039$). This was expected, as lowered LDL-C from birth should influence a physician's decision to prescribe statins later in life. Non-lipid risk factors and participant characteristics were well-balanced between *CETP* PTV carriers and controls (TABLE 1). The only exception was diastolic blood pressure, which was 1.3 mmHg higher in *CETP* PTV carriers ($P=0.043$). It is unclear whether this difference reflects a true effect or was due to multiple comparisons, as previous trials with dalcetrapib, evacetrapib, anacetrapib, and obicetrapib did not report elevations in diastolic blood pressure.[11-13,52] Overall, these data suggests that the allocation to *CETP* PTVs occurred in a random-like manner, making it unlikely that imbalances in ASCVD risk factors influenced the results.

Lifetime CETP inhibition from a *CETP* PTV reduced absolute ASCVD risk by 4.8 percentage points (TABLE 1). The adjusted hazard ratio was 0.65 (95% confidence interval, 0.48–0.90, *P* value = 0.008). This risk reduction corresponded to an average gain

of 1.1 years in ASCVD event-free survival before the age of 80 (**FIGURE 2A**). Although the secondary endpoints had overlapping CIs and were not statistically distinguishable, the association between *CETP* PTVs and the composite ASCVD endpoint seemed to be primarily driven by coronary heart disease and ischemic stroke events (**FIGURE 2B**). Notably, *CETP* PTV carrier status did not significantly affect all-cause mortality but reduced the risk of a composite endpoint of ASCVD or all-cause death (**FIGURE 2B**).

The trans-ancestry meta-analysis included 506,516 individuals: 6908 of African; 36,856 of East Asian; 446,157 of European; and 16,595 of South Asian ancestry. Among them, 679 were *CETP* PTV carriers. There were 95,568 ASCVD cases and 410,948 controls. Between-study heterogeneity was low (Q = 3.39, P value = 0.34, I^2 = 11.5%). Lifetime *CETP* inhibition was associated with a reduced ASCVD risk, with an odds ratio of 0.70 (95% confidence interval, 0.57–0.85, meta-analysis *P* value = 4.7×10^{-4}) (**FIGURE 2C**). Taken together, these results indicate that lifetime CETP inhibition significantly reduces ASCVD risk, with no evidence of this effect being dependent on genetic ancestry.

Step 2

CETP inhibition reduces atherosclerotic disease risk by lowering LDL

Data on ASCVD risk reduction, baseline LDL-C, LDL-C lowering, age, and median or mean time of follow-up were extracted from 47 clinical trials of CETP inhibitors, statins, ezetimibe, and PCSK9 inhibitors. Four trials were excluded because they were not designed to assess treatment effects on clinical cardiovascular endpoints. Eight trials terminated early for efficacy were excluded to prevent inflated effect estimates due to the "winner's curse". One trial was excluded for not reporting outcomes as hazard ratios or incidence rate ratios, making it incomparable to the other trials.

The remaining 34 cardiovascular outcomes trials covered a population of 328,036 individuals with 53,161 ASCVD events across both primary and secondary prevention settings. Three trials studied CETP inhibitors (n_{total}=58,412; n_{events}=7126), 23 trials evaluated statins (n_{total}=160,910; n_{events}=31,854), three examined ezetimibe monotherapy (n_{total}=23,645; n_{events}=6271), two were of ezetimibe/statin combination therapy (n_{total}=11,143; n_{events}=1480), and three investigated PCSK9 inhibitors (n_{total}=73,926; n_{events}=6430). Age at enrollment ranged from 49.8 to 75.4 years, with follow-up durations

between 0.3 and 6.7 years. Baseline LDL-C ranged from 1.58 to 4.97 mmol/L, with reductions between 0.03 and 1.80 mmol/L. Twenty-nine trials were double-blind, and five were not. Further details, including study settings and extracted endpoints, are provided in **SUPPLEMENTAL TABLE 2**.

To determine whether the clinical trial data aligned with the cumulative LDL exposure hypothesis of atherosclerosis, we used multiple meta-regression to assess the impact of LDL-C lowering magnitude and duration on ASCVD risk. We identified a significant interaction between LDL-C reduction and time of follow-up ($P = 0.007$) (see **FIGURE 3**). Sensitivity analyses confirmed the robustness of this association (**SUPPLEMENTAL FIGURES 9-10**). These data support the hypothesis that LDL-C's effect on ASCVD risk follows a cumulative exposure model and provide a theoretical basis for modeling genetic effects alongside clinical trial data, as described next.

We compared genetic and pharmacological CETP inhibition with guideline-recommended lipid-lowering therapies and *LDLR* PTVs to evaluate their effects on ASCVD relative to cumulative LDL-C lowering. We found that the predicted effect of CETP inhibition was similar to the combined estimate from statins, PCSK9 inhibitors, ezetimibe, and *LDLR* PTVs (hazard ratio: 0.76 vs. 0.69 per 10 mmol/L × years) (**FIGURE 4**). Since CETP inhibition and the other pathways produced comparable effects per unit of cumulative LDL-C reduction, these results suggest that CETP inhibition reduces ASCVD risk primarily by lowering LDL-C.

Nine out of eleven lipid-lowering trials with cumulative LDL-C reductions below 2.5 mmol/L × years did not achieve a statistically significant reduction in ASCVD events, as indicated by 95% confidence intervals overlapping the null in **FIGURE 4**. Only two trials (PROVE-IT and IMPROVE-IT) with reductions below this threshold had confidence intervals that did not overlap the null. These data suggest that the LDL-C reductions in the evacetrapib and dalcetrapib trials were too small to yield a statistically significant decrease in ASCVD events. Moreover, this issue appears not to be unique to CETP inhibitors but applies to LDL-C lowering therapies in general. To demonstrate stronger effects on clinical endpoints, future trials could target greater cumulative LDL-C reductions.

Discussion

The failure of the early CETP inhibitors in cardiovascular outcomes trials surprised many and raised doubts about the efficacy of CETP inhibition in ASCVD prevention. In contrast, our study shows that individuals carrying a single defective *CETP* allele since birth, leading to lifelong partial CETP inhibition, have a significantly reduced risk of developing ASCVD. This finding aligns with previous genetic studies on both common and rare loss-of-function *CETP* variants across diverse populations,[32,53-57] reinforcing the potential of CETP inhibition as a promising strategy for ASCVD prevention.

To reconcile the discrepancy between the promising genetic data and mixed clinical trial results, we applied the hypothesis that cumulative lifetime LDL-C exposure plays a critical role in ASCVD development. This concept aligns with the pathophysiology of atherosclerosis, which suggests that both the magnitude and duration of LDL-C exposure drive disease progression through plaque formation.[17] A key strength of our study was the estimation of cumulative LDL-C differences over time, providing a more biologically accurate assessment of LDL-lowering effects on ASCVD risk.

By analyzing data from individuals with *CETP* and *LDLR* PTVs, along with cardiovascular outcomes trials of lipid-lowering therapies, we identified a strong linear relationship between reductions in cumulative LDL-C exposure and decreases in ASCVD risk. Notably, clinical trials that did not achieve substantial and sustained LDL-C reductions over time. regardless of the therapeutic mechanism, including CETP inhibitors, statins, or PCSK9 inhibitors, were significantly less likely to show clinical benefit. These findings suggest that the lack of efficacy seen in the evacetrapib and dalcetrapib trials was not specific to the particular class of drugs but was instead due to insufficient LDL lowering and the short duration of the trials.

Our analysis demonstrated that both LDL-C reduction magnitude and treatment duration were independent predictors of ASCVD risk reduction. Furthermore, we identified a significant interaction between these factors, providing strong support for the cumulative LDL hypothesis. A key strength of the meta-analysis was the use of strict exclusion criteria to eliminate trials that were likely to report inflated effect estimates.[43] Our findings are consistent with another meta-analysis of 21 trials that focused on

minimizing bias from small-study effects while also excluding trials with less than 3 years

of follow-up.[58]

These results indicate that instrumental variable analysis using human

genetics can yield accurate treatment effect estimates when time-varying exposures are

assessed and accounted for. Previous studies have suggested that genetic analyses may

overestimate the impact of LDL-C lowering on ASCVD risk,[50] potentially due to imprecise

measurement of the exposure variable. Specifically, equating exposure to the effect of

genetic variants on LDL-C at a single time point assumes that ASCVD risk reduction is

driven by a constant, time-independent, and absolute LDL-C lowering. Given the

progressive nature of atherosclerosis and the variation in LDL-C levels throughout life,

this assumption may not be valid.

This highlights that an important difference between genetic and

pharmacological effects lies in the timing and duration of exposure and the length of

follow-up. Genetic exposures begin at conception and persist throughout life, whereas

clinical trials administer treatments to adults and generally follow participants for only a

few years. Since atherosclerosis can begin early in life and is driven by cumulative LDL-C

retention,[16,17] accounting for lifelong time-varying exposure is essential for accurate

estimation of treatment effects.

In this study, we addressed this by modeling LDL-C reductions using

population-averaged life-course trajectories. While this method improves accuracy over

assuming time-independent absolute LDL-C reductions, it has limitations. Specifically,

we did not account for individual variations in LDL-C trajectories across different

populations (besides correcting for baseline levels), nor did we consider complex, non-

linear interactions with treatments or risk factors such as diabetes, hypertension,

inflammation, severely elevated Lipoprotein(a) levels, or lifestyle. Future studies should

aim to use within-sample LDL-C trajectories and consider individual-level models to

enhance the precision of cumulative LDL-C exposure measurements.

Another limitation of this study was that we did not investigate genetic CETP

inhibition in its homozygous state. Heterozygous *CETP* PTV carriers showed LDL-C

reductions of –0.19 mmol/L, whereas potent CETP inhibitors reduced LDL-C by up to five

times more (–0.98 mmol/L).[15] From these genetic data, it is unclear whether increased

genetic CETP inhibition leads to proportionally greater benefits. However, anacetrapib

100 mg daily achieved 80% CETP inhibition and demonstrated similar clinical benefits to

CETP PTV carriers (per unit of cumulative LDL-C lowering),[13,59] suggesting that the genetic

effects may be generalizable (**FIGURE 3**).

These findings have important clinical implications that require confirmation

in clinical trials. They suggest that maximizing the benefits of LDL-C lowering depends on

achieving substantial and sustained reductions over extended periods. They also

highlight the need for further research in early intervention and long-term adherence to

both lifestyle and pharmacological lipid-lowering interventions. Future clinical trials

should consider the impact of LDL-C over time in their design to better assess the efficacy

of lipid-lowering therapies for ASCVD prevention.

In conclusion, we predict that future CETP inhibitor trials achieving

substantial and sustained LDL-C lowering will demonstrate efficacy in preventing ASCVD.

Our findings emphasize the importance of sustained LDL-C reduction over time and

support the continued investigation of CETP inhibition as a therapeutic strategy for

ASCVD prevention.

Acknowledgements

This research has been conducted using the UK Biobank Resource under Application Number 148828. We thank the UK Biobank participants for their important contributions to medical research. The graphical abstract was created in BioRender (Landfors, F. (2024) https://BioRender.com/j51i966).

Funding

This work was supported by grants from the Northern Sweden Heart Fund, and received financial support from New Amsterdam Pharma Company N.V.

Conflict of interest

Fredrik Landfors is a part-time clinical scientist at Lipigon Pharmaceuticals AB. John J.P. Kastelein is the chief scientific officer of NewAmsterdam Pharma N.V. Elin Chorell has no conflicts of interest to declare.

Data availability

UK Biobank data is available to authorized researchers. Researchers interested in accessing the data must complete an application process with UK Biobank. The identifiers for the UK Biobank datasets used in the analyses are described in the METHODS section. All publicly available scientific data that were used for the analyses of this paper are provided in the manuscript or supplemental material. Plots were digitized using the University of Tennessee-Knoxville WebPlotDigitizer v.3.4 (https://web.eecs.utk.edu/~dcostine/personal/PowerDeviceLib/DigiTest/index.html).

Legends

Table 1

Characteristics of the European-ancestry United Kingdom Biobank cohort.

All measurements, except for the atherosclerotic cardiovascular disease-related primary and secondary endpoints, were taken at the time of entry into the United Kingdom Biobank. To protect privacy, cell counts of five or fewer are reported as '≤5'.

Figure 1

Comparison of LDL cholesterol trajectories in genetic studies and clinical trials.

This schematic compares LDL cholesterol trajectories from genetic effects versus clinical interventions. The left panel shows a modest, lifelong reduction in LDL cholesterol beginning at conception due to *CETP* protein-truncating variants (PTVs). In contrast, the right panel illustrates a more substantial reduction starting in adulthood, as seen in the Scandinavian Simvastatin Survival Study (4S). Despite differences in onset and magnitude, both approaches lead to similar reductions of cumulative LDL cholesterol exposure over time. The cumulative LDL cholesterol lowering for each scenario corresponds to the values shown on the x-axis of **FIGURE 4**.

Figure 2

Association of *CETP* protein-truncating variants with cardiovascular endpoints.

(A) Kaplan-Meier survival curves comparing cumulative survival (left panel) and event-free survival (right panel) between carriers of *CETP* protein-truncating variants (PTVs) (n = 385) and non-carriers (n = 409,253) in the European-ancestry subset of the UK Biobank. Shaded areas around each curve represent the 95% confidence intervals. Curves were truncated when the at-risk population fell below 10 participants.

(B) Forest plot showing the association between *CETP* PTVs and primary and secondary cardiovascular endpoints.

(C) Forest plot showing the trans-ancestry meta-analysis combining UK Biobank results with data from previous studies of *CETP* PTVs.[32] Ancestries are denoted as: 'Eur' for European, 'Afr.' for African, and 'S. As' for South Asian. 'ASCVD' denotes atherosclerotic cardiovascular disease, and "CHD" denotes coronary heart disease.

 ## Figure 3

 Atherosclerotic risk reduction from the magnitude and duration of LDL cholesterol

 lowering in clinical trials.

Meta-regression scatterplot illustrating the association between atherosclerotic cardiovascular disease (ASCVD) risk reduction and the interaction between LDL-C lowering and median time of follow-up in clinical trials. The clinical trials investigated statins, ezetimibe, PCSK9 and CETP inhibitors. Each point represents a clinical trial, with size of the circles reflecting the weight of the trial in the meta-regression analysis. The solid line shows the association between the observed treatment effects on atherosclerotic vascular disease risk and the cumulative LDL differences (LDL × time) observed during follow-up, and the dashed lines represents the 95% confidence interval (CI).

'QE' denotes test for residual heterogeneity

Figure 4

Relationship between cumulative LDL cholesterol reduction and atherosclerotic cardiovascular disease risk reduction across multiple mechanisms.

The regression scatterplot shows the relationship between cumulative LDL cholesterol (LDL-C) reduction (measured in LDL-C plaque years) and atherosclerotic cardiovascular disease (ASCVD) risk reduction achieved through CETP inhibition, statins, ezetimibe, PCSK9 inhibitors, and the LDL receptor (LDLR). Each point represents a clinical trial or genetics study, with circle sizes reflecting study weight in the meta-analysis. Risk reductions were observed either between treatment arms or between carriers of protein-truncating variants (PTVs) and controls. Solid lines indicate meta-analysis treatment effect estimates, with shaded areas showing 95% confidence intervals (CIs). Individual study effect estimates are marked by data points with attached vertical lines representing 95% CIs.

'HR' denotes hazard ratio, and 'IRR' denotes incidence rate ratio. Drug targets are indicated as: 'HMGCR' for HMG-CoA Reductase (statins), 'NPC1L1' for Niemann-Pick C1-Like 1 (ezetimibe), and 'PCSK9' for PCSK9 inhibitors. 'LDLR PTVs' refer to protein-truncating variants in the LDL receptor.

† To simplify visualization, carriers of *LDLR* PTVs (familial hypercholesterolemia-
associated variants) were used as the reference group. Compared to controls (n =
409,539), *LDLR* PTV carriers (n = 99) had a higher ASCVD risk, with a hazard ratio of 4.44
(95% CI: 3.27–6.04).

Appendices

Supplemental note

R script for estimating LDL-C Plaque Years Difference.
This script provides reproducible code for estimating cumulative LDL cholesterol (LDL-C)
lowering from clinical trials or genetic exposures, as described in the paper.

Supplemental figures

Supplemental figure 1

Association between HDL cholesterol and *CETP* Loss-Of-Function Transcript Effect
Estimator (LOFTEE) protein-truncating variant (PTV) classifications.
Tukey Box plot showing there were no meaningful differences between LOFTEE PTV
classifications with regards to plasma HDL cholesterol (HDL-C) levels. The analysis was
conducted in 357,794 European ancestry United Kingdom Biobank participants. The
association between *CETP* PTV classifications were tested using analysis of variance.
Welch's *F* test indicated unequal variances ($P = 3.0 \times 10^{-25}$). *Post hoc* tests indicated there
were no significant differences between predicted low-confidence and high-confidence
CETP PTVs ($P = 0.55$). However, HDL-C levels were elevated in both high- and low-
confidence *CETP* PTV carriers compared to non-carriers ($P = 2.3 \times 10^{-12}$, and $P = 2.4 \times 10^{-6}$,
respectively). There were only two individuals carrying non-classified predicted *CETP*
PTVs, and their HDL-C levels were nominally higher than non-carriers, but nominally
lower than low- or high-confidence *CETP* PTV carriers ($\hat{\mu}_{mean} = 1.55$ mmol/L). Since the
HDL-C levels were similar across the LOFTEE categories, we conclude that LOFTEE
classifications were irrelevant as they did not predict the *CETP* PTVs impact on CETP
activity as measured through plasma HDL-C concentrations.

Supplemental figure 2

Sensitivity analysis of atherosclerotic risk reduction from cumulative LDL
cholesterol lowering, including trials terminated early due to efficacy.

The meta-analysis followed the same procedure as in **Figure 3** but retained trials that
were stopped early for efficacy.

Supplemental figure 3

Leave-one-out sensitivity analysis of the pooled effect size and heterogeneity for
ASCVD risk reduction from cumulative LDL-C lowering, based on Supplemental
Figure 2.

Each study was sequentially excluded to measure its influence on the overall association.

Supplemental figure 4

Sensitivity analysis of atherosclerotic risk reduction from cumulative LDL
cholesterol lowering, including and penalizing trials terminated early due to efficacy.
The meta-analysis followed the same procedure as in **Figure 4** but included trials
stopped early for efficacy, penalizing their effect estimates (natural logarithm of the
hazard ratio) by multiplication with their information criterion (see the **Methods** section
for definition).

Supplemental figure 5

Leave-one-out sensitivity analysis of the pooled effect size and heterogeneity for
atherosclerotic cardiovascular disease risk reduction from cumulative LDL
cholesterol lowering, based on Supplemental Figure 4.

Each study was sequentially excluded to assess its influence on the overall association.

Supplemental figure 6

Sensitivity analysis of atherosclerotic risk reduction from cumulative LDL
cholesterol lowering, excluding non–double-blind clinical trials.
The meta-analysis was conducted using the same methods as in **Figure 4** but excluded
non–double-blind trials.

Supplemental figure 7

Leave-one-out sensitivity analysis of the pooled effect size and heterogeneity for
atherosclerotic cardiovascular disease risk reduction from cumulative LDL
cholesterol lowering, based on Supplemental Figure 6.

Each study was sequentially excluded to assess its influence on the overall association
between LDL cholesterol reduction and ASCVD risk.

Leave-one-out sensitivity analysis of the pooled effect size and heterogeneity for atherosclerotic cardiovascular disease risk reduction from cumulative LDL cholesterol lowering, based on FIGURE 4.

Each study was sequentially excluded to assess its influence on the overall association between LDL cholesterol reduction and ASCVD risk.

Supplemental Figure 9. Meta-regression analyses for atherosclerotic disease risk reduction based on LDL-C reduction times the median time of follow-up.

(A) The left scatterplot regression line shows the association between LDL-C (low-density lipoprotein cholesterol) reduction and atherosclerotic cardiovascular disease (ASCVD) risk reduction conditioning on median time of follow-up. The right scatterplot regression line shows ASCVD risk as a function of adjusted median time of follow-up by LDL-C reduction.

(B) The scatterplots show meta-regressions with an interaction term between LDL-C reduction and median time of follow-up. The top plot regression slope shows the adjusted ASCVD risk as a function of the interaction between LDL-C reduction and median time of follow-up (mmol/L × years). The two bottom plots show the separate effects of LDL-C reduction (left) and median time of follow-up (right) on ASCVD risk, taking the interaction term into account.

Dashed lines indicate confidence intervals. Larger circle sizes correspond to studies with greater weight in the analysis. 'HR' denotes hazard ratio, and 'IRR' denotes incidence rate ratio.

Supplemental Figure 10. Meta-regression sensitivity and multi-model inference analyses

(A) The table shows adjusted models of the interaction between LDL cholesterol (LDL-C) reduction and the median time of follow-ups across atherosclerotic cardiovascular disease (ASCVD) risk reduction in clinical trials. Model 1 includes the interaction between LDL-C reduction and median time of follow-up, while models 2–6 adds a single adjustment for either baseline LDL-C, annualized risk, cumulative risk, mean age, and

year of publication. The interaction regression coefficients (β), standard errors (SE), p-values, and permutation-based p-values are shown in separate columns.

(B) This bar plot shows the ranking of the importance of predictor variables in explaining ASCVD risk reduction as observed in the clinical trials.

Supplemental tables

Supplemental table 1

UK Biobank *CETP* protein-truncating variants.

This table lists the protein-truncating variants (PTVs) in *CETP* (encoding the cholesteryl ester transfer protein) that were analyzed in the United Kingdom Biobank (see **STEP 1**). It includes variant identifiers, genomic positions, allele frequencies, and Ensembl Variant Effect Predictor predicted consequences.

Supplemental table 2

Cumulative LDL cholesterol exposure versus atherosclerotic cardiovascular disease risk.

This table includes summary data from clinical trials and genetic association studies relevant to the analysis of cumulative LDL cholesterol exposure in relation to atherosclerotic cardiovascular disease risk, which are presented in **FIGURE 3** and **SUPPLEMENTAL FIGURES 2-12**.

Supplemental table 3

UK Biobank *LDLR* protein-truncating variants.

This table lists the protein-truncating variants (PTVs) in *LDLR* (encoding the low-density lipoprotein receptor) that were analyzed in the United Kingdom Biobank (see **STEP 1**). It includes variant identifiers, genomic positions, allele frequencies, and Ensembl Variant Effect Predictor predicted consequences.

Supplemental table 4

Low-density lipoprotein cholesterol life-course trajectories.

This table presents averaged life-course trajectories of low-density lipoprotein (LDL) cholesterol levels derived from population-based cohorts.[17,46,47] These data were used in the analyses presented in **FIGURE 1**, **FIGURE 4**, and **SUPPLEMENTAL FIGURES 2–8**.

References

References

1. Morton RE, Zilversmit DB. Purification and characterization of lipid transfer
protein(s) from human lipoprotein-deficient plasma. *J Lipid Res*. Sep 1982;23(7):1058-
67.
2. Drayna D, Jarnagin AS, McLean J, et al. Cloning and sequencing of human
cholesteryl ester transfer protein cDNA. *Nature*. 1987 Jun 18-24 1987;327(6123):632-4.
doi:10.1038/327632a0
3. Tall AR, Rader DJ. Trials and Tribulations of CETP Inhibitors. *Circ Res*. Jan 05
2018;122(1):106-112. doi:10.1161/CIRCRESAHA.117.311978
4. Millar JS, Reyes-Soffer G, Jumes P, et al. Anacetrapib lowers LDL by
increasing ApoB clearance in mildly hypercholesterolemic subjects. *J Clin Invest*. Jun
2015;125(6):2510-22. doi:10.1172/JCI80025
5. Ikewaki K, Nishiwaki M, Sakamoto T, et al. Increased catabolic rate of low
density lipoproteins in humans with cholesteryl ester transfer protein deficiency. *J Clin
Invest*. Sep 1995;96(3):1573-81. doi:10.1172/JCI118196
6. Nicholls SJ, Ruotolo G, Brewer HB, et al. Cholesterol Efflux Capacity and
Pre-Beta-1 HDL Concentrations Are Increased in Dyslipidemic Patients Treated With
Evacetrapib. *J Am Coll Cardiol*. Nov 17 2015;66(20):2201-2210.
doi:10.1016/j.jacc.2015.09.013
7. Yvan-Charvet L, Kling J, Pagler T, et al. Cholesterol efflux potential and
antiinflammatory properties of high-density lipoprotein after treatment with niacin or
anacetrapib. *Arterioscler Thromb Vasc Biol*. Jul 2010;30(7):1430-8.
doi:10.1161/ATVBAHA.110.207142
8. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at
high risk for coronary events. *N Engl J Med*. Nov 22 2007;357(21):2109-22.
doi:10.1056/NEJMoa0706628
9. Johns DG, Duffy J, Fisher T, Hubbard BK, Forrest MJ. On- and off-target
pharmacology of torcetrapib: current understanding and implications for the structure
activity relationships (SAR), discovery and development of cholesteryl ester-transfer
protein (CETP) inhibitors. *Drugs*. Mar 05 2012;72(4):491-507. doi:10.2165/11599310-
000000000-00000
10. Kastelein JJP, Hsieh A, Dicklin MR, Ditmarsch M, Davidson MH. Obicetrapib:
Reversing the Tide of CETP Inhibitor Disappointments. *Curr Atheroscler Rep*. Feb
2024;26(2):35-44. doi:10.1007/s11883-023-01184-1
11. Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with
a recent acute coronary syndrome. *N Engl J Med*. Nov 29 2012;367(22):2089-99.
doi:10.1056/NEJMoa1206797
12. Lincoff AM, Nicholls SJ, Riesmeyer JS, et al. Evacetrapib and Cardiovascular
Outcomes in High-Risk Vascular Disease. *N Engl J Med*. May 18 2017;376(20):1933-
1942. doi:10.1056/NEJMoa1609581
13. Bowman L, Hopewell JC, Chen F, et al. Effects of Anacetrapib in Patients
with Atherosclerotic Vascular Disease. *N Engl J Med*. Sep 28 2017;377(13):1217-1227.
doi:10.1056/NEJMoa1706444
14. Johns DG, Wang SP, Rosa R, et al. Impact of drug distribution into adipose
on tissue function: The cholesteryl ester transfer protein (CETP) inhibitor anacetrapib as
a test case. *Pharmacol Res Perspect*. Dec 2019;7(6):e00543. doi:10.1002/prp2.543

15. Nicholls SJ, Ditmarsch M, Kastelein JJ, et al. Lipid lowering effects of the
CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized
phase 2 trial. *Nat Med*. Aug 2022;28(8):1672-1678. doi:10.1038/s41591-022-01936-7
16. HOLMAN RL, McGILL HC, STRONG JP, GEER JC. The natural history of
atherosclerosis: the early aortic lesions as seen in New Orleans in the middle of the of
the 20th century. *Am J Pathol*. 1958;34(2):209-35.
17. Ference BA, Braunwald E, Catapano AL. The LDL cumulative exposure
hypothesis: evidence and practical applications. *Nat Rev Cardiol*. Oct 2024;21(10):701-
716. doi:10.1038/s41569-024-01039-5
18. Rivas MA, Pirinen M, Conrad DF, et al. Human genomics. Effect of predicted
protein-truncating genetic variants on the human transcriptome. *Science*. May 08
2015;348(6235):666-9. doi:10.1126/science.1261877
19. DeBoever C, Tanigawa Y, Lindholm ME, et al. Medical relevance of protein-
truncating variants across 337,205 individuals in the UK Biobank study. *Nat Commun*.
Apr 24 2018;9(1):1612. doi:10.1038/s41467-018-03910-9
20. Dhindsa RS, Burren OS, Sun BB, et al. Rare variant associations with
plasma protein levels in the UK Biobank. *Nature*. Oct 2023;622(7982):339-347.
doi:10.1038/s41586-023-06547-x
21. Minikel EV, Karczewski KJ, Martin HC, et al. Evaluating drug targets through
human loss-of-function genetic variation. *Nature*. May 2020;581(7809):459-464.
doi:10.1038/s41586-020-2267-z
22. Trajanoska K, Bhérer C, Taliun D, Zhou S, Richards JB, Mooser V. From target
discovery to clinical drug development with human genetics. *Nature*. Aug
2023;620(7975):737-745. doi:10.1038/s41586-023-06388-8
23. Minikel EV, Painter JL, Dong CC, Nelson MR. Refining the impact of genetic
evidence on clinical success. *Nature*. May 2024;629(8012):624-629.
doi:10.1038/s41586-024-07316-0
24. Sudlow C, Gallacher J, Allen N, et al. UK biobank: an open access resource
for identifying the causes of a wide range of complex diseases of middle and old age.
PLoS Med. Mar 2015;12(3):e1001779. doi:10.1371/journal.pmed.1001779
25. Szustakowski JD, Balasubramanian S, Kvikstad E, et al. Advancing human
genetics research and drug discovery through exome sequencing of the UK Biobank. *Nat
Genet*. Jul 2021;53(7):942-948. doi:10.1038/s41588-021-00885-0
26. McLaren W, Gil L, Hunt SE, et al. The Ensembl Variant Effect Predictor.
Genome Biol. Jun 06 2016;17(1):122. doi:10.1186/s13059-016-0974-4
27. Karczewski KJ, Francioli LC, Tiao G, et al. The mutational constraint
spectrum quantified from variation in 141,456 humans. *Nature*. May
2020;581(7809):434-443. doi:10.1038/s41586-020-2308-7
28. Yamamoto K, Sonehara K, Namba S, et al. Genetic footprints of assortative
mating in the Japanese population. *Nat Hum Behav*. Jan 2023;7(1):65-73.
doi:10.1038/s41562-022-01438-z
29. Abdellaoui A, Hugh-Jones D, Yengo L, et al. Genetic correlates of social
stratification in Great Britain. *Nat Hum Behav*. Dec 2019;3(12):1332-1342.
doi:10.1038/s41562-019-0757-5
30. Howe LJ, Nivard MG, Morris TT, et al. Within-sibship genome-wide
association analyses decrease bias in estimates of direct genetic effects. *Nat Genet*.
May 2022;54(5):581-592. doi:10.1038/s41588-022-01062-7

31.   Manichaikul A, Mychaleckyj JC, Rich SS, Daly K, Sale M, Chen WM. Robust
relationship inference in genome-wide association studies. *Bioinformatics*. Nov 15
2010;26(22):2867-73. doi:10.1093/bioinformatics/btq559
32.   Nomura A, Won HH, Khera AV, et al. Protein-Truncating Variants at the
Cholesteryl Ester Transfer Protein Gene and Risk for Coronary Heart Disease. *Circ Res*.
Jun 23 2017;121(1):81-88. doi:10.1161/CIRCRESAHA.117.311145
33.   FIRTH D. BIAS REDUCTION OF MAXIMUM-LIKELIHOOD-ESTIMATES. Article.
Biometrika. MAR 1993 1993;80(1):27-38. doi:10.1093/biomet/80.1.27
34.   Burger PM, Dorresteijn JAN, Koudstaal S, et al. Course of the effects of LDL-
cholesterol reduction on cardiovascular risk over time: A meta-analysis of 60
randomized controlled trials. *Atherosclerosis*. Sep 2024;396:118540.
doi:10.1016/j.atherosclerosis.2024.118540
35.   Khan SU, Khan MU, Valavoor S, et al. Association of lowering apolipoprotein
B with cardiovascular outcomes across various lipid-lowering therapies: Systematic
review and meta-analysis of trials. *Eur J Prev Cardiol*. Aug 2020;27(12):1255-1268.
doi:10.1177/2047487319871733
36.   Navarese EP, Robinson JG, Kowalewski M, et al. Association Between
Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A
Systematic Review and Meta-analysis. *JAMA*. Apr 17 2018;319(15):1566-1579.
doi:10.1001/jama.2018.2525
37.   Wanner C, Krane V, März W, et al. Atorvastatin in patients with type 2
diabetes mellitus undergoing hemodialysis. *N Engl J Med*. Jul 21 2005;353(3):238-48.
doi:10.1056/NEJMoa043545
38.   Fellström BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and
cardiovascular events in patients undergoing hemodialysis. *N Engl J Med*. Apr 02
2009;360(14):1395-407. doi:10.1056/NEJMoa0810177
39.   Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with
systolic heart failure. *N Engl J Med*. Nov 29 2007;357(22):2248-61.
doi:10.1056/NEJMoa0706201
40.   Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on
early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a
randomized controlled trial. *JAMA*. Apr 04 2001;285(13):1711-8.
doi:10.1001/jama.285.13.1711
41.   Taguchi I, Iimuro S, Iwata H, et al. High-Dose Versus Low-Dose Pitavastatin
in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD): A Randomized
Superiority Trial. *Circulation*. May 08 2018;137(19):1997-2009.
doi:10.1161/CIRCULATIONAHA.117.032615
42.   Grinspoon SK, Fitch KV, Zanni MV, et al. Pitavastatin to Prevent
Cardiovascular Disease in HIV Infection. *N Engl J Med*. Aug 24 2023;389(8):687-699.
doi:10.1056/NEJMoa2304146
43.   Bassler D, Briel M, Montori VM, et al. Stopping randomized trials early for
benefit and estimation of treatment effects: systematic review and meta-regression
analysis. *JAMA*. Mar 24 2010;303(12):1180-7. doi:10.1001/jama.2010.310
44.   Hernán MA. The hazards of hazard ratios. *Epidemiology*. Jan 2010;21(1):13-
5. doi:10.1097/EDE.0b013e3181c1ea43

45.   McGowan MP, Hosseini Dehkordi SH, Moriarty PM, Duell PB. Diagnosis and
Treatment of Heterozygous Familial Hypercholesterolemia. *J Am Heart Assoc*. Dec 17
2019;8(24):e013225. doi:10.1161/JAHA.119.013225
46.   Gozlan O, Gross D, Gruener N. Lipoprotein levels in newborns and
adolescents. *Clin Biochem*. Aug 1994;27(4):305-6. doi:10.1016/0009-9120(94)90033-7
47.   Skinner AC, Steiner MJ, Chung AE, Perrin EM. Cholesterol curves to identify
population norms by age and sex in healthy weight children. *Clin Pediatr (Phila)*. Mar
2012;51(3):233-7. doi:10.1177/0009922811430344
48.   Labrecque JA, Swanson SA. Interpretation and Potential Biases of
Mendelian Randomization Estimates With Time-Varying Exposures. *Am J Epidemiol*. Jan
01 2019;188(1):231-238. doi:10.1093/aje/kwy204
49.   Morris TT, Heron J, Sanderson ECM, Davey Smith G, Didelez V, Tilling K.
Interpretation of Mendelian randomization using a single measure of an exposure that
varies over time. *Int J Epidemiol*. Dec 13 2022;51(6):1899-1909. doi:10.1093/ije/dyac136
50.   Burgess S, Butterworth A, Malarstig A, Thompson SG. Use of Mendelian
randomisation to assess potential benefit of clinical intervention. *BMJ*. Nov 06
2012;345:e7325. doi:10.1136/bmj.e7325
51.   Higgins JP, Thompson SG. Controlling the risk of spurious findings from
meta-regression. *Stat Med*. Jun 15 2004;23(11):1663-82. doi:10.1002/sim.1752
52.   Hovingh GK, Kastelein JJ, van Deventer SJ, et al. Cholesterol ester transfer
protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised,
double-blind, placebo-controlled phase 2 trial. *Lancet*. Aug 01 2015;386(9992):452-60.
doi:10.1016/S0140-6736(15)60158-1
53.   Johannsen TH, Frikke-Schmidt R, Schou J, Nordestgaard BG, Tybjærg-
Hansen A. Genetic inhibition of CETP, ischemic vascular disease and mortality, and
possible adverse effects. *J Am Coll Cardiol*. Nov 13 2012;60(20):2041-8.
doi:10.1016/j.jacc.2012.07.045
54.   Ference BA, Kastelein JJP, Ginsberg HN, et al. Association of Genetic
Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and
Cardiovascular Risk. *JAMA*. Sep 12 2017;318(10):947-956.
doi:10.1001/jama.2017.11467
55.   Nordestgaard LT, Christoffersen M, Lauridsen BK, et al. Long-term Benefits
and Harms Associated With Genetic Cholesteryl Ester Transfer Protein Deficiency in the
General Population. *JAMA Cardiol*. Jan 01 2022;7(1):55-64.
doi:10.1001/jamacardio.2021.3728
56.   Cupido AJ, Reeskamp LF, Hingorani AD, et al. Joint Genetic Inhibition of
PCSK9 and CETP and the Association With Coronary Artery Disease: A Factorial
Mendelian Randomization Study. *JAMA Cardiol*. Sep 01 2022;7(9):955-964.
doi:10.1001/jamacardio.2022.2333
57.   Dunca D, Chopade S, Gordillo-Marañón M, et al. Comparing the effects of
CETP in East Asian and European ancestries: a Mendelian randomization study. Article.
Nature Communications. JUN 21 2024 2024;15(1)ARTN 5302. doi:10.1038/s41467-024-
49109-z
58.   Wang N, Woodward M, Huffman MD, Rodgers A. Compounding Benefits of
Cholesterol-Lowering Therapy for the Reduction of Major Cardiovascular Events:
Systematic Review and Meta-Analysis. *Circ Cardiovasc Qual Outcomes*. Jun
2022;15(6):e008552. doi:10.1161/CIRCOUTCOMES.121.008552

59.   Krishna R, Bergman AJ, Jin B, et al. Multiple-dose pharmacodynamics and
pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP)
inhibitor, in healthy subjects. *Clin Pharmacol Ther*. Dec 2008;84(6):679-83.
doi:10.1038/clpt.2008.109

(GRAPHICAL ABSTRACT)

STUDY OF CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) INHIBITION

High-density lipoprotein

Low-density lipoprotein & Very-low density lipoprotein

Does cumulative LDL cholesterol exposure differences explain the mixed results of CETP inhibitors in cardiovascular outcomes trials?

Cholesteryl Esters

CETP

Triglycerides

Defective or Reduced Quantitites of Protein

Pharmacological Inhibition

Protein-Truncating Variant

CETP Gene

5'   3'

CETP Inhibitors

Plasma

1. Cumulative LDL exposure drives atherosclerosis risk:

Time × LDL determines reduction of cardiovascular events in clinical trials, suggesting long-term LDL reduction is key to lowering atherosclerosis risk

Treatment Effect (Hazard Ratio)

Time × LDL

2. Lifelong genetic CETP inhibition reduces cardiovascular events by lowering LDL:

Life-course LDL Difference

— Non−carrier Control
··· Variant Carrier

LDL

Age

Life-course Disease Risk

Hazard ratio, 0.65 (95% CI, 0.48−0.90).

Events

Controls

CETP PTV Carriers

Age

3. Mixed CETP inhibitor trial results reflect insufficient cumulative LDL lowering:

Treatment Effect (Hazard Ratio)

Cumulative LDL Difference

Inconsistent trial outcomes are attributable to inadequate cumulative LDL reduction, highlighting the need for more prolonged LDL lowering in future trials

(TABLE 1)   <u>Step 1</u>

Table 1. Cohort characteristics   <u>Mean (95% CI) / No. (%)</u>

	Complete observations (% missing)	Controls (n = 409 253)	Heterozygous *CETP* PTV carriers (n = 385)	*P* value
Age (years)	409 638 (0.0%)	56.8 (56.8-56.8)	56.7 (55.9-57.4)	0.71
Male	409 638 (0.0%)	188 542 (46.1%)	178 (46.2%)	0.96
Blood pressure (mmHg)				
Systolic	382 697 (6.6%)	139.9 (139.9-140.0)	140.8 (138.7-142.9)	0.41
Diastolic	382 708 (6.6%)	82.2 (82.2-82.2)	83.5 (82.2-84.7)	0.043
Weight (kg)	408 454 (0.3%)	78.2 (78.2-78.3)	78.1 (76.5-79.7)	0.92
BMI (kg/m^2)	408 306 (0.4%)	27.4 (27.4-27.4)	27.4 (27.0-27.9)	0.88
Self-reported diabetes status at recruitment	408 727 (0.3%)	19 783 (4.8%)	21 (5.5%)	0.55
Self-reported smoking status at recruitment	408 234 (0.4%)	42 677 (10.4%)	37 (9.6%)	0.68
Self-reported statin usage at recruitment	408 511 (0.3%)	66 879 (16.3%)	48 (12.5%)	0.039
Lipids (mmol/L)				
HDL cholesterol	357 796 (12.7%)	1.45 (1.45-1.45)	1.87 (1.81-1.92)	9×10^{-37}
LDL cholesterol, direct	390 187 (4.8%)	3.57 (3.57-3.57)	3.39 (3.30-3.47)	3×10^{-5}
LDL cholesterol, Friedewald	357 486 (12.8%)	3.46 (3.46-3.47)	3.23 (3.13-3.34)	2×10^{-5}
Non-HDL cholesterol	357 731 (12.7%)	4.26 (4.26-4.26)	4.05 (3.94-4.16)	2×10^{-4}
Remnant cholesterol	357 145 (12.9%)	0.69 (0.69-0.69)	0.65 (0.62-0.68)	0.017
Triglycerides	390 628 (4.7%)	1.75 (1.75-1.76)	1.78 (1.67-1.90)	0.06
Lipoproteins				
Apolipoprotein B (g/L)	389 028 (5.1%)	1.04 (1.03-1.04)	0.97 (0.95-1.00)	6×10^{-7}
Apolipoprotein A-I (g/L)	355 784 (13.2%)	1.54 (1.54-1.54)	1.73 (1.70-1.77)	6×10^{-23}
Lipoprotein(a) (nmol/L)	311 427 (24.0%)	44.0 (43.8-44.2)	37.5 (32.9-43.0)	0.021
Endpoints during follow-up				
Primary				
Any atherosclerotic disease	409 638 (0.0%)	61052 (14.9%)	39 (10.1%)	0.008
Secondary				
Coronary heart disease	409 638 (0.0%)	52666 (12.9%)	35 (9.1%)	0.027
Ischemic stroke	409 638 (0.0%)	10491 (2.6%)	6 (1.6%)	0.26
Myocardial infarction	409 631 (0.1%)	20600 (5.0%)	17 (4.4%)	0.73
Cardiovascular death	409 638 (0.0%)	4167 (1.0%)	≤5 (≤1.3%)	
Major adverse cardiovascular events	409 633 (0.1%)	29484 (7.2%)	21 (5.5%)	0.20
Peripheral atherosclerosis	409 638 (0.0%)	3667 (0.9%)	≤5 (≤1.3%)	
All-cause death	409 638 (0.0%)	36641 (9.0%)	27 (7.0%)	0.21
Any atherosclerotic disease or all-cause death	409 638 (0.0%)	83510 (20.4%)	59 (15.3%)	0.013

(FIGURE 1)

A. Cumulative LDL Cholesterol Exposure Difference when the Trajectory is Altered by Genetics

B. Cumulative LDL Cholesterol Exposure Difference when the Trajectory is Altered in a Drug Trial

$$\text{LDL–C Plaque Years Difference} = \left| \int_{t=0}^{t} \text{LDL–C(Exposed)} \, dt - \int_{t=0}^{t} \text{LDL–C(Not Exposed)} \, dt \right|$$

A. Survival Analysis of Atherosclerotic Events in the UK Biobank

Cumulative Events:

Hazard ratio, 0.65 (95% CI, 0.48–0.90).

Controls

CETP PTV Carriers

No. at Risk (%)

Ctrl	408538 (100)	403397 (99)	341176 (83)	206277 (50)	39582 (10)
PTV	385 (100)	383 (99)	332 (86)	201 (52)	34 (9)

Event-free Survival:

CETP PTV Carriers

Controls

Mean Event–free Survival (Age=80):
Ctrl, 77.0 Years (95% CI, 76.9–77.0).
PTV, 78.1 Years (95% CI, 77.5–78.7).

	408540 (100)	402891 (98)	340509 (83)	206241 (50)	39714 (10)
	387 (100)	384 (99)	334 (86)	202 (52)	35 (9)
Ctrl	408538 (100)	403397 (99)	341176 (83)	206277 (50)	39582 (10)
PTV	385 (100)	383 (99)	332 (86)	201 (52)	34 (9)

B. Association of *CETP* PTVs with UK Biobank Cardiovascular Endpoints

Endpoint	Hazard ratio (95% CI)	
Any atherosclerotic event (61 091 cases)	0.65 (0.48–0.90)	
Coronary heart disease (52 701 cases)	0.69 (0.49–0.96)	
Ischemic stroke (10 497 cases)	0.61 (0.27–1.36)	
Myocardial infarction (20 617 cases)	0.87 (0.54–1.40)	
Cardiovascular death (4169 cases)	0.52 (0.13–2.06)	
Major adverse cardiovascular events (29 505 cases)	0.75 (0.49–1.14)	
Peripheral atherosclerosis (3671 cases)	1.18 (0.44–3.15)	
All–cause death (36 669 cases)	0.80 (0.55–1.16)	
Any atherosclerotic event or all–cause death (83 570 cases)	0.72 (0.56–0.93)	

0.1   1.0   10
Hazard ratio (95% CI)

C. Trans-Ancestry Meta-Analysis of *CETP* PTVs

Endpoint	Odds ratio (95% CI)	
UK Biobank, Any ASCVD Eur. (61 091 cases)	0.64 (0.46– 0.90)	
UK Biobank, Any ASCVD Afr. (715 cases)	1.57 (0.27– 9.01)	
UK Biobank, Any ASCVD S.As. (1528 cases)	3.08 (0.46–20.74)	
Nomura et al. 2017, CHD Trans–ancestry (32 234 cases)	0.70 (0.54– 0.90)	
Pooled estimate (95 568 cases)	**0.70 (0.57– 0.85)**	

Meta-analysis *P* value = 4.7 × 10⁻⁴
Heterogeneity: Q = 3.39, *P* value = 0.34, *I²* = 11.5%

0.1   1.0   10
Odds ratio (95% CI)

(FIGURE 3)

ASCVD Risk Reduction vs. Interaction between LDL-C Lowering and Time of Follow-up

(FIGURE 4)

Comparison of ASCVD Risk Reduction and Cumulative LDL-C Exposure: CETP Inhibition vs. Guideline-Recommended Lipid-Lowering Therapies and *LDLR* PTVs

CETP Inhibition
Hazard ratio, 0.76 per 10–mmol/L × years (95% CI, 0.64–0.89)
Heterogeneity: Q = 2.4 (Het. *P* value = 0.49), I^2 = 0%

Other (HMGCR, NPC1L1, PCSK9, *LDLR*)
Hazard ratio, 0.69 per 10–mmol/L × years (95% CI, 0.66–0.71)
Heterogeneity: Q = 41.2 (Het. *P* value = 0.11), I^2 = 24.7%

(SUPPLEMENTAL FIGURE 2)

Comparison of ASCVD Risk and Cumulative LDL-C Exposure: CETP Inhibition vs. Guideline-Recommended Lipid-Lowering Therapies and *LDLR* PTVs

(SUPPLEMENTAL FIGURE 3)

Effect size & Heterogeneity

Leave-one-out effect size sensitivity analysis of statins, ezetimibe, PCSK9 inhibition, and *LDLR* PTVs

Sorted by Effect Size

Omitting LDLR PTVs (Genetic)	$\hat{\theta}_{-i} = -0.44$ [-0.48–-0.39]; $I^2 = 39\%$
Omitting 4S (Simvastatin, HMGCR)	$\hat{\theta}_{-i} = -0.41$ [-0.44–-0.37]; $I^2 = 46\%$
Omitting CORONA (Rosuvastatin, HMGCR)	$\hat{\theta}_{-i} = -0.40$ [-0.43–-0.36]; $I^2 = 47\%$
Omitting SEARCH (Simvastatin, HMGCR)	$\hat{\theta}_{-i} = -0.39$ [-0.43–-0.36]; $I^2 = 48\%$
Omitting SEAS (Simvastatin/Ezetimibe, HMGCR/NPC1L1)	$\hat{\theta}_{-i} = -0.39$ [-0.43–-0.36]; $I^2 = 49\%$
Omitting IMPROVE–IT (Ezetimibe, NPC1L1)	$\hat{\theta}_{-i} = -0.39$ [-0.43–-0.36]; $I^2 = 49\%$
Omitting AURORA (Rosuvastatin, HMGCR)	$\hat{\theta}_{-i} = -0.39$ [-0.43–-0.36]; $I^2 = 49\%$
Omitting 4D (Atorvastatin, HMGCR)	$\hat{\theta}_{-i} = -0.39$ [-0.43–-0.36]; $I^2 = 49\%$
Omitting ASPEN (Atorvastatin, HMGCR)	$\hat{\theta}_{-i} = -0.39$ [-0.43–-0.36]; $I^2 = 49\%$
Omitting ALLHAT–LLT (Pravastatin, HMGCR)	$\hat{\theta}_{-i} = -0.39$ [-0.43–-0.36]; $I^2 = 49\%$
Omitting ALERT (Fluvastatin, HMGCR)	$\hat{\theta}_{-i} = -0.39$ [-0.43–-0.36]; $I^2 = 49\%$
Omitting GISSI–P (Pravastatin, HMGCR)	$\hat{\theta}_{-i} = -0.39$ [-0.43–-0.36]; $I^2 = 49\%$
Omitting RACING (Ezetimibe, NPC1L1)	$\hat{\theta}_{-i} = -0.39$ [-0.43–-0.36]; $I^2 = 49\%$
Omitting MIRACL (Atorvastatin, HMGCR)	$\hat{\theta}_{-i} = -0.39$ [-0.43–-0.35]; $I^2 = 49\%$
Omitting HIJ–PROPER (Ezetimibe, NPC1L1)	$\hat{\theta}_{-i} = -0.39$ [-0.43–-0.35]; $I^2 = 49\%$
Omitting A to Z (Simvastatin, HMGCR)	$\hat{\theta}_{-i} = -0.39$ [-0.43–-0.35]; $I^2 = 49\%$
Omitting SHARP (Simvastatin/Ezetimibe, HMGCR/NPC1L1)	$\hat{\theta}_{-i} = -0.39$ [-0.43–-0.35]; $I^2 = 49\%$
Omitting SPIRE 1 & 2 (Bococizumab, PCSK9)	$\hat{\theta}_{-i} = -0.39$ [-0.43–-0.35]; $I^2 = 48\%$
Omitting ALLIANCE (Atorvastatin, HMGCR)	$\hat{\theta}_{-i} = -0.39$ [-0.43–-0.35]; $I^2 = 49\%$
Omitting LIPS (Fluvastatin, HMGCR)	$\hat{\theta}_{-i} = -0.39$ [-0.43–-0.35]; $I^2 = 49\%$
Omitting SPARCL (Atorvastatin, HMGCR)	$\hat{\theta}_{-i} = -0.39$ [-0.43–-0.35]; $I^2 = 49\%$
Omitting PROSPER (Pravastatin, HMGCR)	$\hat{\theta}_{-i} = -0.39$ [-0.43–-0.35]; $I^2 = 49\%$
Omitting TST (Statin/Ezetimibe, HMGCR/NPC1L1)	$\hat{\theta}_{-i} = -0.39$ [-0.43–-0.35]; $I^2 = 48\%$
Omitting REPRIEVE (Pitavastatin, HMGCR)	$\hat{\theta}_{-i} = -0.39$ [-0.43–-0.35]; $I^2 = 48\%$
Omitting AF/TexCAPS (Lovastatin, HMGCR)	$\hat{\theta}_{-i} = -0.39$ [-0.43–-0.35]; $I^2 = 49\%$
Omitting ODYSSEY OUTCOMES (Alirocumab, PCSK9)	$\hat{\theta}_{-i} = -0.39$ [-0.43–-0.35]; $I^2 = 49\%$
Omitting MEGA (Pravastatin, HMGCR)	$\hat{\theta}_{-i} = -0.39$ [-0.43–-0.35]; $I^2 = 48\%$
Omitting CARE (Pravastatin, HMGCR)	$\hat{\theta}_{-i} = -0.39$ [-0.43–-0.35]; $I^2 = 49\%$
Omitting PROVE–IT (Atorvastatin, HMGCR)	$\hat{\theta}_{-i} = -0.39$ [-0.43–-0.35]; $I^2 = 47\%$
Omitting HOPE 3 (Rosuvastatin, HMGCR)	$\hat{\theta}_{-i} = -0.39$ [-0.43–-0.35]; $I^2 = 49\%$
Omitting REAL–CAD (Pitavastatin, HMGCR)	$\hat{\theta}_{-i} = -0.39$ [-0.42–-0.35]; $I^2 = 46\%$
Omitting LIPID (Pravastatin, HMGCR)	$\hat{\theta}_{-i} = -0.39$ [-0.43–-0.35]; $I^2 = 49\%$
Omitting ASCOT–LLA (Atorvastatin, HMGCR)	$\hat{\theta}_{-i} = -0.39$ [-0.42–-0.35]; $I^2 = 48\%$
Omitting FOURIER (Evolucumab, PCSK9)	$\hat{\theta}_{-i} = -0.39$ [-0.42–-0.35]; $I^2 = 48\%$
Omitting CARDS (Atorvastatin, HMGCR)	$\hat{\theta}_{-i} = -0.39$ [-0.42–-0.35]; $I^2 = 47\%$
Omitting WOSCOPS (Pravastatin, HMGCR)	$\hat{\theta}_{-i} = -0.39$ [-0.42–-0.35]; $I^2 = 48\%$
Omitting IDEAL (Atorvastatin, HMGCR)	$\hat{\theta}_{-i} = -0.39$ [-0.42–-0.35]; $I^2 = 48\%$
Omitting JUPITER (Rosuvastatin, HMGCR)	$\hat{\theta}_{-i} = -0.39$ [-0.42–-0.35]; $I^2 = 30\%$
Omitting TNT (Atorvastatin, HMGCR)	$\hat{\theta}_{-i} = -0.38$ [-0.42–-0.35]; $I^2 = 45\%$
Omitting HPS (Simvastatin, HMGCR)	$\hat{\theta}_{-i} = -0.38$ [-0.41–-0.34]; $I^2 = 45\%$

Effect Size (Fixed–Effect Model)

Leave-one-out effect size sensitivity analysis of CETP inhibition

Sorted by Effect Size

Omitting ACCELERATE (Evacetrapib, CETP)	$\hat{\theta}_{-i} = -0.31$ [-0.49–-0.14]; $I^2 = 0\%$
Omitting REVEAL (Anacetrapib, CETP)	$\hat{\theta}_{-i} = -0.30$ [-0.56–-0.04]; $I^2 = 17\%$
Omitting dal–OUTCOMES (Dalcetrapib, CETP)	$\hat{\theta}_{-i} = -0.28$ [-0.45–-0.11]; $I^2 = 0\%$
Omitting CETP PTVs (Genetic)	$\hat{\theta}_{-i} = -0.23$ [-0.43–-0.02]; $I^2 = 0\%$

Effect Size (Fixed–Effect Model)

(SUPPLEMENTAL FIGURE 4)

Comparison of ASCVD Risk and Cumulative LDL-C Exposure: CETP Inhibition vs. Guideline-Recommended Lipid-Lowering Therapies and *LDLR* PTVs

Effect size & Heterogeneity

Leave-one-out effect size sensitivity analysis of statins, ezetimibe, PCSK9 inhibition, and *LDLR* PTVs

Sorted by Effect Size

Omitted study	Estimate
Omitting LDLR PTVs (Genetic)	$\hat{\theta}_{-i} = -0.42\ [-0.47--0.38]; I^2 = 12\%$
Omitting 4S (Simvastatin, HMGCR)	$\hat{\theta}_{-i} = -0.40\ [-0.43--0.36]; I^2 = 24\%$
Omitting CORONA (Rosuvastatin, HMGCR)	$\hat{\theta}_{-i} = -0.39\ [-0.42--0.35]; I^2 = 25\%$
Omitting SEARCH (Simvastatin, HMGCR)	$\hat{\theta}_{-i} = -0.38\ [-0.42--0.35]; I^2 = 28\%$
Omitting SEAS (Simvastatin/Ezetimibe, HMGCR/NPC1L1)	$\hat{\theta}_{-i} = -0.38\ [-0.42--0.35]; I^2 = 28\%$
Omitting IMPROVE–IT (Ezetimibe, NPC1L1)	$\hat{\theta}_{-i} = -0.38\ [-0.42--0.35]; I^2 = 29\%$
Omitting AURORA (Rosuvastatin, HMGCR)	$\hat{\theta}_{-i} = -0.38\ [-0.42--0.35]; I^2 = 28\%$
Omitting 4D (Atorvastatin, HMGCR)	$\hat{\theta}_{-i} = -0.38\ [-0.42--0.35]; I^2 = 29\%$
Omitting ASPEN (Atorvastatin, HMGCR)	$\hat{\theta}_{-i} = -0.38\ [-0.42--0.35]; I^2 = 29\%$
Omitting ALLHAT–LLT (Pravastatin, HMGCR)	$\hat{\theta}_{-i} = -0.38\ [-0.42--0.35]; I^2 = 29\%$
Omitting ALERT (Fluvastatin, HMGCR)	$\hat{\theta}_{-i} = -0.38\ [-0.42--0.35]; I^2 = 29\%$
Omitting GISSI–P (Pravastatin, HMGCR)	$\hat{\theta}_{-i} = -0.38\ [-0.42--0.35]; I^2 = 29\%$
Omitting RACING (Ezetimibe, NPC1L1)	$\hat{\theta}_{-i} = -0.38\ [-0.42--0.35]; I^2 = 29\%$
Omitting MIRACL (Atorvastatin, HMGCR)	$\hat{\theta}_{-i} = -0.38\ [-0.42--0.35]; I^2 = 28\%$
Omitting AF/TexCAPS (Lovastatin, HMGCR)	$\hat{\theta}_{-i} = -0.38\ [-0.42--0.35]; I^2 = 29\%$
Omitting HIJ–PROPER (Ezetimibe, NPC1L1)	$\hat{\theta}_{-i} = -0.38\ [-0.42--0.35]; I^2 = 29\%$
Omitting TST (Statin/Ezetimibe, HMGCR/NPC1L1)	$\hat{\theta}_{-i} = -0.38\ [-0.42--0.35]; I^2 = 29\%$
Omitting A to Z (Simvastatin, HMGCR)	$\hat{\theta}_{-i} = -0.38\ [-0.42--0.35]; I^2 = 28\%$
Omitting SPIRE 1 & 2 (Bococizumab, PCSK9)	$\hat{\theta}_{-i} = -0.38\ [-0.42--0.35]; I^2 = 27\%$
Omitting REAL–CAD (Pitavastatin, HMGCR)	$\hat{\theta}_{-i} = -0.38\ [-0.42--0.35]; I^2 = 28\%$
Omitting SHARP (Simvastatin/Ezetimibe, HMGCR/NPC1L1)	$\hat{\theta}_{-i} = -0.38\ [-0.42--0.35]; I^2 = 29\%$
Omitting REPRIEVE (Pitavastatin, HMGCR)	$\hat{\theta}_{-i} = -0.38\ [-0.42--0.35]; I^2 = 28\%$
Omitting ALLIANCE (Atorvastatin, HMGCR)	$\hat{\theta}_{-i} = -0.38\ [-0.42--0.35]; I^2 = 28\%$
Omitting LIPS (Fluvastatin, HMGCR)	$\hat{\theta}_{-i} = -0.38\ [-0.42--0.35]; I^2 = 29\%$
Omitting PROSPER (Pravastatin, HMGCR)	$\hat{\theta}_{-i} = -0.38\ [-0.42--0.35]; I^2 = 29\%$
Omitting ASCOT–LLA (Atorvastatin, HMGCR)	$\hat{\theta}_{-i} = -0.38\ [-0.42--0.35]; I^2 = 29\%$
Omitting CARDS (Atorvastatin, HMGCR)	$\hat{\theta}_{-i} = -0.38\ [-0.42--0.35]; I^2 = 28\%$
Omitting LIPID (Pravastatin, HMGCR)	$\hat{\theta}_{-i} = -0.38\ [-0.42--0.34]; I^2 = 29\%$
Omitting SPARCL (Atorvastatin, HMGCR)	$\hat{\theta}_{-i} = -0.38\ [-0.42--0.34]; I^2 = 29\%$
Omitting MEGA (Pravastatin, HMGCR)	$\hat{\theta}_{-i} = -0.38\ [-0.42--0.34]; I^2 = 26\%$
Omitting ODYSSEY OUTCOMES (Alirocumab, PCSK9)	$\hat{\theta}_{-i} = -0.38\ [-0.42--0.34]; I^2 = 29\%$
Omitting PROVE–IT (Atorvastatin, HMGCR)	$\hat{\theta}_{-i} = -0.38\ [-0.42--0.34]; I^2 = 25\%$
Omitting CARE (Pravastatin, HMGCR)	$\hat{\theta}_{-i} = -0.38\ [-0.42--0.34]; I^2 = 28\%$
Omitting HOPE 3 (Rosuvastatin, HMGCR)	$\hat{\theta}_{-i} = -0.38\ [-0.42--0.34]; I^2 = 28\%$
Omitting FOURIER (Evolucumab, PCSK9)	$\hat{\theta}_{-i} = -0.38\ [-0.42--0.34]; I^2 = 28\%$
Omitting WOSCOPS (Pravastatin, HMGCR)	$\hat{\theta}_{-i} = -0.38\ [-0.42--0.34]; I^2 = 27\%$
Omitting JUPITER (Rosuvastatin, HMGCR)	$\hat{\theta}_{-i} = -0.38\ [-0.41--0.34]; I^2 = 12\%$
Omitting IDEAL (Atorvastatin, HMGCR)	$\hat{\theta}_{-i} = -0.38\ [-0.41--0.34]; I^2 = 26\%$
Omitting TNT (Atorvastatin, HMGCR)	$\hat{\theta}_{-i} = -0.38\ [-0.41--0.34]; I^2 = 21\%$
Omitting HPS (Simvastatin, HMGCR)	$\hat{\theta}_{-i} = -0.37\ [-0.40--0.33]; I^2 = 19\%$

Effect Size (Fixed–Effect Model) (axis: −0.5, −0.4, −0.3, −0.2, −0.1)

Leave-one-out effect size sensitivity analysis of CETP inhibition

Sorted by Effect Size

Omitted study	Estimate
Omitting ACCELERATE (Evacetrapib, CETP)	$\hat{\theta}_{-i} = -0.31\ [-0.49--0.14]; I^2 = 0\%$
Omitting REVEAL (Anacetrapib, CETP)	$\hat{\theta}_{-i} = -0.30\ [-0.56--0.04]; I^2 = 17\%$
Omitting dal–OUTCOMES (Dalcetrapib, CETP)	$\hat{\theta}_{-i} = -0.28\ [-0.45--0.11]; I^2 = 0\%$
Omitting CETP PTVs (Genetic)	$\hat{\theta}_{-i} = -0.23\ [-0.43--0.02]; I^2 = 0\%$

Effect Size (Fixed–Effect Model) (axis: −0.50, −0.25, 0.00, 0.25)

(SUPPLEMENTAL FIGURE 6)

Comparison of ASCVD Risk and Cumulative LDL-C Exposure: CETP Inhibition vs. Guideline-Recommended Lipid-Lowering Therapies and *LDLR* PTVs

(SUPPLEMENTAL FIGURE 7)

Effect size & Heterogeneity

Leave-one-out effect size sensitivity analysis of statins, ezetimibe, PCSK9 inhibition, and *LDLR* PTVs

Sorted by Effect Size

Omitting LDLR PTVs (Genetic)	$\hat{\theta}_\cdot = -0.41\ [-0.46\text{--}-0.37];\ I^2 = 15\%$
Omitting 4S (Simvastatin, HMGCR)	$\hat{\theta}_\cdot = -0.39\ [-0.43\text{--}-0.35];\ I^2 = 29\%$
Omitting CORONA (Rosuvastatin, HMGCR)	$\hat{\theta}_\cdot = -0.38\ [-0.42\text{--}-0.34];\ I^2 = 29\%$
Omitting SEARCH (Simvastatin, HMGCR)	$\hat{\theta}_\cdot = -0.38\ [-0.41\text{--}-0.34];\ I^2 = 33\%$
Omitting SEAS (Simvastatin/Ezetimibe, HMGCR/NPC1L1)	$\hat{\theta}_\cdot = -0.38\ [-0.41\text{--}-0.34];\ I^2 = 33\%$
Omitting IMPROVE–IT (Ezetimibe, NPC1L1)	$\hat{\theta}_\cdot = -0.37\ [-0.41\text{--}-0.34];\ I^2 = 34\%$
Omitting AURORA (Rosuvastatin, HMGCR)	$\hat{\theta}_\cdot = -0.37\ [-0.41\text{--}-0.34];\ I^2 = 33\%$
Omitting 4D (Atorvastatin, HMGCR)	$\hat{\theta}_\cdot = -0.37\ [-0.41\text{--}-0.34];\ I^2 = 34\%$
Omitting ASPEN (Atorvastatin, HMGCR)	$\hat{\theta}_\cdot = -0.37\ [-0.41\text{--}-0.34];\ I^2 = 34\%$
Omitting ALERT (Fluvastatin, HMGCR)	$\hat{\theta}_\cdot = -0.37\ [-0.41\text{--}-0.34];\ I^2 = 34\%$
Omitting MIRACL (Atorvastatin, HMGCR)	$\hat{\theta}_\cdot = -0.37\ [-0.41\text{--}-0.34];\ I^2 = 33\%$
Omitting A to Z (Simvastatin, HMGCR)	$\hat{\theta}_\cdot = -0.37\ [-0.41\text{--}-0.34];\ I^2 = 33\%$
Omitting SPIRE 1 & 2 (Bococizumab, PCSK9)	$\hat{\theta}_\cdot = -0.37\ [-0.41\text{--}-0.34];\ I^2 = 32\%$
Omitting SHARP (Simvastatin/Ezetimibe, HMGCR/NPC1L1)	$\hat{\theta}_\cdot = -0.37\ [-0.41\text{--}-0.34];\ I^2 = 34\%$
Omitting LIPS (Fluvastatin, HMGCR)	$\hat{\theta}_\cdot = -0.37\ [-0.41\text{--}-0.34];\ I^2 = 34\%$
Omitting PROSPER (Pravastatin, HMGCR)	$\hat{\theta}_\cdot = -0.37\ [-0.41\text{--}-0.34];\ I^2 = 33\%$
Omitting PROVE–IT (Atorvastatin, HMGCR)	$\hat{\theta}_\cdot = -0.37\ [-0.41\text{--}-0.34];\ I^2 = 29\%$
Omitting ODYSSEY OUTCOMES (Alirocumab, PCSK9)	$\hat{\theta}_\cdot = -0.37\ [-0.41\text{--}-0.33];\ I^2 = 33\%$
Omitting CARE (Pravastatin, HMGCR)	$\hat{\theta}_\cdot = -0.37\ [-0.41\text{--}-0.34];\ I^2 = 33\%$
Omitting SPARCL (Atorvastatin, HMGCR)	$\hat{\theta}_\cdot = -0.37\ [-0.41\text{--}-0.33];\ I^2 = 34\%$
Omitting HOPE 3 (Rosuvastatin, HMGCR)	$\hat{\theta}_\cdot = -0.37\ [-0.41\text{--}-0.33];\ I^2 = 33\%$
Omitting LIPID (Pravastatin, HMGCR)	$\hat{\theta}_\cdot = -0.37\ [-0.41\text{--}-0.33];\ I^2 = 33\%$
Omitting FOURIER (Evolucumab, PCSK9)	$\hat{\theta}_\cdot = -0.37\ [-0.41\text{--}-0.33];\ I^2 = 32\%$
Omitting WOSCOPS (Pravastatin, HMGCR)	$\hat{\theta}_\cdot = -0.37\ [-0.41\text{--}-0.33];\ I^2 = 31\%$
Omitting IDEAL (Atorvastatin, HMGCR)	$\hat{\theta}_\cdot = -0.37\ [-0.41\text{--}-0.33];\ I^2 = 29\%$
Omitting TNT (Atorvastatin, HMGCR)	$\hat{\theta}_\cdot = -0.37\ [-0.40\text{--}-0.33];\ I^2 = 22\%$
Omitting HPS (Simvastatin, HMGCR)	$\hat{\theta}_\cdot = -0.36\ [-0.39\text{--}-0.32];\ I^2 = 18\%$

Effect Size (Fixed–Effect Model)

Leave-one-out effect size sensitivity analysis of CETP inhibition

Sorted by Effect Size

Omitting ACCELERATE (Evacetrapib, CETP)	$\hat{\theta}_\cdot = -0.31\ [-0.49\text{--}-0.14];\ I^2 = 0\%$
Omitting REVEAL (Anacetrapib, CETP)	$\hat{\theta}_\cdot = -0.30\ [-0.56\text{--}-0.04];\ I^2 = 17\%$
Omitting dal–OUTCOMES (Dalcetrapib, CETP)	$\hat{\theta}_\cdot = -0.28\ [-0.45\text{--}-0.11];\ I^2 = 0\%$
Omitting CETP PTVs (Genetic)	$\hat{\theta}_\cdot = -0.23\ [-0.43\text{--}-0.02];\ I^2 = 0\%$

Effect Size (Fixed–Effect Model)

(SUPPLEMENTAL FIGURE 8)

Effect size & Heterogeneity

Leave-one-out effect size sensitivity analysis of statins, ezetimibe, PCSK9 inhibition, and *LDLR* PTVs

Sorted by Effect Size

Omitting LDLR PTVs (Genetic)	$\hat{\theta}_. = -0.42\ [-0.46--0.37];\ I^2 = 7\%$
Omitting 4S (Simvastatin, HMGCR)	$\hat{\theta}_. = -0.39\ [-0.43--0.35];\ I^2 = 22\%$
Omitting CORONA (Rosuvastatin, HMGCR)	$\hat{\theta}_. = -0.38\ [-0.42--0.34];\ I^2 = 22\%$
Omitting SEARCH (Simvastatin, HMGCR)	$\hat{\theta}_. = -0.38\ [-0.42--0.34];\ I^2 = 26\%$
Omitting SEAS (Simvastatin/Ezetimibe, HMGCR/NPC1L1)	$\hat{\theta}_. = -0.38\ [-0.41--0.34];\ I^2 = 26\%$
Omitting IMPROVE–IT (Ezetimibe, NPC1L1)	$\hat{\theta}_. = -0.38\ [-0.41--0.34];\ I^2 = 27\%$
Omitting AURORA (Rosuvastatin, HMGCR)	$\hat{\theta}_. = -0.38\ [-0.41--0.34];\ I^2 = 26\%$
Omitting 4D (Atorvastatin, HMGCR)	$\hat{\theta}_. = -0.38\ [-0.41--0.34];\ I^2 = 27\%$
Omitting ASPEN (Atorvastatin, HMGCR)	$\hat{\theta}_. = -0.38\ [-0.41--0.34];\ I^2 = 27\%$
Omitting ALLHAT–LLT (Pravastatin, HMGCR)	$\hat{\theta}_. = -0.38\ [-0.41--0.34];\ I^2 = 27\%$
Omitting ALERT (Fluvastatin, HMGCR)	$\hat{\theta}_. = -0.38\ [-0.41--0.34];\ I^2 = 27\%$
Omitting RACING (Ezetimibe, NPC1L1)	$\hat{\theta}_. = -0.38\ [-0.41--0.34];\ I^2 = 27\%$
Omitting MIRACL (Atorvastatin, HMGCR)	$\hat{\theta}_. = -0.38\ [-0.41--0.34];\ I^2 = 26\%$
Omitting HIJ–PROPER (Ezetimibe, NPC1L1)	$\hat{\theta}_. = -0.38\ [-0.41--0.34];\ I^2 = 27\%$
Omitting A to Z (Simvastatin, HMGCR)	$\hat{\theta}_. = -0.38\ [-0.41--0.34];\ I^2 = 26\%$
Omitting SPIRE 1 & 2 (Bococizumab, PCSK9)	$\hat{\theta}_. = -0.38\ [-0.41--0.34];\ I^2 = 25\%$
Omitting ALLIANCE (Atorvastatin, HMGCR)	$\hat{\theta}_. = -0.38\ [-0.41--0.34];\ I^2 = 26\%$
Omitting SHARP (Simvastatin/Ezetimibe, HMGCR/NPC1L1)	$\hat{\theta}_. = -0.38\ [-0.41--0.34];\ I^2 = 27\%$
Omitting LIPS (Fluvastatin, HMGCR)	$\hat{\theta}_. = -0.38\ [-0.41--0.34];\ I^2 = 27\%$
Omitting PROSPER (Pravastatin, HMGCR)	$\hat{\theta}_. = -0.38\ [-0.41--0.34];\ I^2 = 27\%$
Omitting MEGA (Pravastatin, HMGCR)	$\hat{\theta}_. = -0.37\ [-0.41--0.34];\ I^2 = 23\%$
Omitting PROVE–IT (Atorvastatin, HMGCR)	$\hat{\theta}_. = -0.37\ [-0.41--0.34];\ I^2 = 22\%$
Omitting ODYSSEY OUTCOMES (Alirocumab, PCSK9)	$\hat{\theta}_. = -0.37\ [-0.41--0.34];\ I^2 = 27\%$
Omitting SPARCL (Atorvastatin, HMGCR)	$\hat{\theta}_. = -0.37\ [-0.41--0.34];\ I^2 = 27\%$
Omitting CARE (Pravastatin, HMGCR)	$\hat{\theta}_. = -0.37\ [-0.41--0.34];\ I^2 = 26\%$
Omitting HOPE 3 (Rosuvastatin, HMGCR)	$\hat{\theta}_. = -0.37\ [-0.41--0.34];\ I^2 = 26\%$
Omitting LIPID (Pravastatin, HMGCR)	$\hat{\theta}_. = -0.37\ [-0.41--0.34];\ I^2 = 26\%$
Omitting FOURIER (Evolucumab, PCSK9)	$\hat{\theta}_. = -0.37\ [-0.41--0.34];\ I^2 = 25\%$
Omitting WOSCOPS (Pravastatin, HMGCR)	$\hat{\theta}_. = -0.37\ [-0.41--0.34];\ I^2 = 24\%$
Omitting IDEAL (Atorvastatin, HMGCR)	$\hat{\theta}_. = -0.37\ [-0.41--0.34];\ I^2 = 23\%$
Omitting TNT (Atorvastatin, HMGCR)	$\hat{\theta}_. = -0.37\ [-0.41--0.33];\ I^2 = 15\%$
Omitting HPS (Simvastatin, HMGCR)	$\hat{\theta}_. = -0.36\ [-0.40--0.32];\ I^2 = 12\%$

Effect Size (Fixed–Effect Model)

Leave-one-out effect size sensitivity analysis of CETP inhibition

Sorted by Effect Size

Omitting ACCELERATE (Evacetrapib, CETP)	$\hat{\theta}_. = -0.31\ [-0.49--0.14];\ I^2 = 0\%$
Omitting REVEAL (Anacetrapib, CETP)	$\hat{\theta}_. = -0.30\ [-0.56--0.04];\ I^2 = 17\%$
Omitting dal–OUTCOMES (Dalcetrapib, CETP)	$\hat{\theta}_. = -0.28\ [-0.45--0.11];\ I^2 = 0\%$
Omitting CETP PTVs (Genetic)	$\hat{\theta}_. = -0.23\ [-0.43--0.02];\ I^2 = 0\%$

Effect Size (Fixed–Effect Model)

(SUPPLEMENTAL FIGURE 9)

A. Meta-Regression Without Interaction Term

(Formula = Atherosclerotic Disease Risk Reduction ~ LDL-C Reduction + Time of Follow-up)

B. Meta-Regression With Interaction Term

(Formula = Atherosclerotic Disease Risk Reduction ~ LDL-C Reduction + Time of Follow-up + LDL-C Reduction × Time of Follow-up)

(SUPPLEMENTAL FIGURE 10)

A. Meta-Regression Table of Adjusted Models

	SUPPLEMENTAL FIGURE 10. Meta-Regression Sensitivity Analysis				
Model	**Independent variables**	$\beta_{\text{LDL-C} \times}$ Follow-Up	$\text{SE}_{\text{LDL-C} \times}$ Follow-Up	*P* value	*P* value (Permutation)
1	LDL-C Reduction, Time of Follow-Up, LDL-C Reduction × Time of Follow-Up	-0.0378	0.0131	0.0074	0.0090
2	1 + Baseline LDL-C	-0.0343	0.0131	0.0136	0.0180
3	1 + Annualized ASCVD event risk	-0.0384	0.0161	0.0236	0.0290
4	1 + Cumulative ASCVD event risk	-0.0361	0.0133	0.0113	0.0110
5	1 + Mean Age at Baseline	-0.0327	0.0128	0.0164	0.0250
6	1 + Year published	-0.0356	0.0125	0.0079	0.0060

B. Multi-Model Inference Analysis